1. A method for reducing the risk of type 2 diabetes progression in a patient diagnosed with a disease or condition selected from the group consisting of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), where the method comprises administering to the patient a therapeutically effective dosage prolonged-acting insulin, wherein said therapeutically effective dosage of said prolonged-acting insulin reduces the risk of type 2 diabetes progression in a given patient. A method of reducing the risk of new angina pectoris in a patient diagnosed with a disease or condition selected from the group consisting of impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes, where the patient is diagnosed with diabetes 2 type, either does not take drugs, or takes an oral antidiabetic agent, where the method comprises administering to the indicated patient a therapeutically effective dosage of prolonged-acting insulin, with The indicated therapeutically effective dosage of the indicated prolonged-acting insulin reduces the risk of new angina pectoris. 3. A method for reducing the risk of a microvascular event in a patient who is diagnosed with a disease or condition selected from the group consisting of impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes, where the patient is diagnosed with type 2 diabetes, either does not take drugs, or takes an oral antidiabetic agent, where the method is prescribed1. Способ снижения риска прогрессирования диабета 2 типа у пациента, у которого диагностировано заболевание или состояние, выбранное из группы, состоящей из нарушенного уровня глюкозы натощак (IFG) и нарушенной толерантности к глюкозе (IGT), где способ предусматривает введение указанному пациенту терапевтически эффективной дозировки инсулина пролонгированного действия, при этом указанная терапевтически эффективная дозировка указанного инсулина пролонгированного действия снижает риск прогрессирования диабета
